Extend Biosciences receives an SBIR supplemental award
The company received an Administrative Supplement award from NCI to further the development of the long-acting ghrelin asset for the treatment of cancer cachexia.
The company received an Administrative Supplement award from NCI to further the development of the long-acting ghrelin asset for the treatment of cancer cachexia.